<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2885">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773015</url>
  </required_header>
  <id_info>
    <org_study_id>GE-067-027</org_study_id>
    <nct_id>NCT04773015</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe</brief_title>
  <official_title>A Post-Authorisation Safety Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the effectiveness of the VIZAMYL™ reader training programme in&#xD;
      clinical practice in Europe&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Actual">December 7, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the diagnostic accuracy determined across all images (at least 200 images), as indicators of the collective proficiency of the clinical readers at interpreting VIZAMYL™ PET images obtained in clinical practice</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>Diagnostic accuracy is defined as the (number of true positives + number of true negatives) / total number of evaluable images. The 95% exact binomial confidence interval of the accuracy estimate will also be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the diagnostic sensitivity determined across all images (at least 200 images), as indicators of the collective proficiency of the clinical readers at interpreting VIZAMYL™ PET images obtained in clinical practice</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>The sensitivity is defined as the number of true positives / (number of true positives + number of false negatives). The 95% exact binomial confidence interval of the sensitivity will also be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the specificity determined across all images (at least 200 images), as indicators of the collective proficiency of the clinical readers at interpreting VIZAMYL™ PET images obtained in clinical practice</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>The specificity is defined as the number of true negatives / (number of true negatives + number of false positives). The 95% exact binomial confidence interval of the specificity will also be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the positive predictive value (PPV) determined across all images (at least 200 images), as indicators of the collective proficiency of the clinical readers at interpreting VIZAMYL™ PET images obtained in clinical practice</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>The PPV is defined as the number of true positives / (number of true positives + number of false positives). The 95% exact binomial confidence interval of the specificity will also be provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the negative predictive value (NPV) determined across all images (at least 200 images), as indicators of the collective proficiency of the clinical readers at interpreting VIZAMYL™ PET images obtained in clinical practice</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>The NPV is defined as the number of true negatives / (number of true negatives + number of false negatives). The 95% exact binomial confidence interval of the specificity will also be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of demographic and other factors (such as method of training, gap between training and reading, and country) on diagnostic accuracy to try to identify factors that may be associated with image interpretation errors</measure>
    <time_frame>Duration of 1 VIZAMYL™ injection and PET scan, approximately 90 minutes.</time_frame>
    <description>Diagnostic accuracy, estimated as (number of true positives + number of true negatives) / total number of evaluable images, will be provided for different subgroups of demographic and other factors.</description>
  </secondary_outcome>
  <enrollment type="Actual">212</enrollment>
  <condition>Cognitive Impairment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        tertiary referral&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is an adult (aged 18 years or older) of any race or gender and has been&#xD;
             referred for a VIZAMYL™ PET brain scan as part of the assessment of his/her cognitive&#xD;
             impairment.&#xD;
&#xD;
          -  The VIZAMYL™ scan was ordered as part of the clinical care of the subject and is not&#xD;
             exclusively for a clinical trial.&#xD;
&#xD;
          -  If informed consent is required by the local IEC, the subject, or his/her legally&#xD;
             authorised representative, is willing and able to sign consent for use of their&#xD;
             de-identified VIZAMYL™ PET images and associated anatomic images (brain CT and/or MRI)&#xD;
             used in the interpretation of the VIZAMYL™ images as well as de-identified demographic&#xD;
             information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If informed consent is required by the local IEC, the subject (or representative) is&#xD;
             not willing to consent to their de-identified images and other data being used in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sherwin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kepler Universittsklinikum Neuromed Campus</name>
      <address>
        <city>Linz</city>
        <state>Wagner-Jauregg-Weg</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Vocklabruck</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00209</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedal Mons Dimicolli - Barletta</name>
      <address>
        <city>Barletta</city>
        <zip>70051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Medicina Nucleare- ASSST Spedali Civili P.O. di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi - S.O.D. Patologia Medica</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2022</last_update_submitted>
  <last_update_submitted_qc>July 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vizamyl</keyword>
  <keyword>flutemetamol</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

